BACKGROUND: Although breast cancer often is perceived to be indolent in older women, breast cancer outcomes in the oldest patients are variable. In the current study, the authors examined breast cancer-specific death by age, stage, and disease subtype in a large, population-based cohort. METHODS: Using Surveillance, Epidemiology, and End Results data, a total of 486,118 women diagnosed with American Joint Committee on Cancer stage I to IV breast cancer between 2000 and 2012 were identified. Using a series of Fine and Gray regression models to account for competing risk, the authors examined the risk of breast cancer-specific death by age and stage (I-IV) for subcohorts with hormone receptor (HR)-positive, HR-negative, human epidermal growth factor receptor 2positive, and triple-negative disease, adjusting for demographic and clinical variables. RESULTS: Overall, 18% of women were aged 65 to 74 years, 13% were aged 75 to 84 years, and 4% were aged 85 years. Regardless of stage of disease within the HR-positive and HR-negative cohorts, patients aged 75 years (vs those aged 55-64 years) experienced a higher adjusted hazard of breast cancerspecific death, which was particularly evident for those with early-stage, HR-positive disease (hazard ratio for those aged 75-84 years, 1.88 [95% confidence interval, 1.68-2.09] and hazard ratio for those aged 85 years, 3.59 [95% confidence interval, 3.12-4.13] [both for stage I disease]). In the cohorts with human epidermal growth factor receptor 2-positive and triple-negative disease, women aged 70 years had a consistently higher risk of breast cancer-specific death across disease stages (vs those aged 51-60 years), with the exception of stage IV triple-negative disease. CONCLUSIONS: Older patients experience worse breast cancer outcomes, regardless of disease subtype and stage. With an increasing number of older patients anticipated to develop breast cancer in the future, addressing disparities for older patients must emerge as a clinical and research priority.
INTRODUCTION
Although breast cancer diagnosed in older women often is perceived to be a more indolent disease compared with that observed in younger women because of its favorable tumor biology, 1 early stages of disease at presentation, 2 and competing risks of death, 3 the outcomes of older patients with breast cancer are highly variable, 2, 3 and it is at the extremes of age at which patients are at risk of the worst breast cancer outcomes. 2, [4] [5] [6] Despite the fact that many older patients are more likely to die of non-breast cancer causes when diagnosed with early stages of breast cancer (particularly when coexisting comorbidity is advanced), 3, 7, 8 their breast cancer outcomes also can be worse than that of their younger counterparts. Currently, women aged 70 years represent approximately 31% of all annual breast cancer cases, yet they account for 47% of all breast cancer-specific deaths. 9 Furthermore, the improvements noted in breast cancer survival over time have occurred at a slower rate for those aged 75 years compared with improvements observed in younger patients. 6 Past studies have described differences in survival by age overall 4 and within the older populations studied within Surveillance, Epidemiology, and End Results (SEER)-Medicare database who have early-stage disease. 2 Although differences in disease biology and subtypes have been explored by age to some degree, 4, 5, 10 to the best of our knowledge current data are limited regarding age-related differences in breast cancer-specific survival by disease stage and subtype. To better understand potential disparities for the oldest patients with breast cancer, we examined the risk of breast cancer-specific deaths among adult women with stage I to IV breast cancer by age, stage of disease, and disease subtype among women diagnosed with breast cancer during a modern era: 2000 through 2012.
MATERIALS AND METHODS

Data Source and Study Population
We identified a cohort of patients in the SEER registry with a first diagnosis of stage I to IV breast cancer. The 17 population-based SEER cancer registries cover areas that represent approximately 28% of the US population and uniformly collect information regarding patient demographics, tumor characteristics, initial treatment, and mortality for all incident cancers. 11 Because this study used registry data, it was deemed exempt for review by the Office for Human Research Studies at Dana-Farber Cancer Institute.
We identified a total of 487,983 women who were diagnosed with their first stage I to IV breast cancer between January 1, 2000, and December 31, 2012, who had cancer histologies likely to be treated by standard guidelines and who were not diagnosed at the time of autopsy/death. Women with bilateral cancers (due to potential misclassification from differing subtypes and stages; 1768 patients), those of unknown age or who were aged <18 years (18 patients), and those who had invalid coding for survival months (79 patients) were excluded, with a final analytic cohort of 486,118 women. Further subcohorts were created to examine outcomes in those women with stage I, II, III, and (de novo) IV disease and in those with varying subtypes as described below.
Outcome Measures
The primary outcome of interest was breast cancerspecific death, with death due to other causes considered a competing event. The interval of survival time was defined as the date of diagnosis until the date of death from any cause or the date of censoring at the last followup date available (12/31/2013) . We ascertained deaths and causes of death from National Death Index data provided with the SEER files.
Independent Variables
Our independent variables of interest included age, American Joint Committee on Cancer (AJCC) sixth edition breast cancer stage (stage I, II, III, or IV), and breast cancer subtype. Age was defined as 35 years, 36 to 44 years, 45 to 54 years, 55 to 64 years, 65 to 74 years, 75 to 84 years, and 85 years for all models except those examining outcomes for those patients with human epidermal growth factor receptor 2 (HER2)-positive disease and triple-negative disease because HER2 status was only available for the years 2010 through 2012 and sample sizes were substantially smaller than those of other cohorts. In the HER2-positive and triple-negative models, we categorized age as <40 years, 40 to 50 years, 51 to 60 years, 61 to 70 years, and >70 years. Breast cancer subtype was categorized using hormone receptor (HR) status and HER2 status. For HR status, having estrogen receptor-positive and/or progesterone receptor-positive disease was categorized as HR-positive disease, having estrogen receptor-negative and progesterone receptornegative disease was categorized as HR-negative disease, and the remaining cases were classified as HR-unknown disease. HER2 status (available during 2010-2012) was categorized as positive, negative, and unknown/borderline. Triple-negative disease was defined for those patients diagnosed between 2010 and 2012 only and required HR-negative and HER2-negative disease. In cohorts in which we restricted to specific disease subtypes (eg, HRpositive, HER2-positive, or triple-negative disease), those patients with unknown values for HR or HER2 were excluded.
Control Variables
Control variables included race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, and other/ unknown), year of diagnosis, marital status (married, single/separated/divorced/widowed, and unknown), SEER region (Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta/rural Georgia, California, Kentucky, Louisiana, and New Jersey), and tumor grade (low/ intermediate, high, and unknown).
Statistical Analysis
We first defined cohorts by stage of disease (stage I-IV) and age group for all 486,118 women. Next, we defined subcohorts of women by disease stage and subtype, categorized by stage for those with HR-positive, HR-negative, HER2-positive, and triple-negative disease. We then examined the number of deaths and causes of death by age and stage of disease overall and used Kaplan-Meier estimates to describe the overall survival and cumulative incidence of death in each cohort. Inference regarding breast cancer-specific survival was made using a series of Fine and Gray regression models, 12 allowing for a subdistribution of hazards of death due to breast cancer when considering death due to other causes as a competing event.
We performed sequential Fine and Gray models for each of the 4 stage-specific cohorts, after adjustment by the control variables described above, followed by 16 more models in which we repeated analyses for each stage (stage I-IV) but with the additional categorization by tumor subtype for the following subcohort models: a) HR-positive disease, adjusting for all control variables (except HR status); b) HR-negative disease, adjusting for all control variables (except HR status); c) HER2-positive disease (2010-2012 diagnoses); and d) triple-negative disease (2010-2012 diagnoses). For models (c) and (d), we adjusted for all variables except HER2 status.
In the univariate and multivariate competing risk regression models, Wald-type tests were conducted of main effects and interaction terms, using a 2-sided P value of <.05 to conclude statistical significance. Point estimates are reported with 95% confidence intervals (95% CIs). All statistical analyses were conducted using SAS statistical software (version 9.4; SAS Institute Inc, Cary, NC).
RESULTS
Among the 486,118 women with breast cancer who were identified, approximately 3% were aged 35 years at the time of diagnosis, 11% were aged 36 to 44 years, 24% were aged 45 to 54 years, 25% were aged 55 to 64 years, 18% were aged 65 to 74 years, 13% were aged 75 to 84 years, and 4% were aged 85 years. Overall, 47%, 35%, 13%, and 5% of patients, respectively, presented with stage I to IV disease. Sample sizes and the distribution of age groups by cohort are shown in Table 1 . Additional patient and disease characteristics by stage and by age group are summarized in Supporting Table 1 . Briefly, the majority of women were white (65%-76% for stage I-IV disease) and most had HR-positive disease, but the prevalence decreased with stage (80% of patients with stage I disease to 61% of patients with stage IV disease). Among those diagnosed in 2010 through 2012, HER2-positive cancers occurred in 11% of patients with stage I disease, 16% of patients with stage II disease, 21% of patients with stage III disease, and 22% of patients with stage IV disease (see Supporting Table 1) .
A total of 105,058 deaths were observed, 57,480 of which (55%) were related to breast cancer, and 47,578 of which (45%) were attributed to other causes. Among patients without a death recorded, the median follow-up time was 6.0 years (interquartile range, 3.2-9.5 years). The risk of death over a median of 6 years of follow-up increased with age, occurring in 2640 women aged 35 years (20%), 7797 women aged 36 to 44 years (15%), 15,471 women aged 45 to 54 years (13%), 18,381 women aged 55 to 64 years (15%), 20,349 women aged 65 to 74 years (22%), 26,978 women aged 75 to 84 years (42%), Overall survival by stage of disease is shown in Figure 1A , and the cumulative incidences of breast cancerspecific deaths and deaths from other causes are shown in Figures 1B and 1C , respectively. The cumulative incidence of deaths due to breast cancer at 5 years was 1.9% (95% CI, 1.8%-2.0%) for stage I disease, 8.0% (95% CI, 7.9%-8.2%) for stage II disease, 26.6% (95% CI, 26.2%-27.0%) for stage III disease, and 70.2% (95% CI, 70.0%-70.8%) for stage IV disease.
Supporting Figure 1 shows the cumulative incidence of breast cancer-specific death by age group in each cohort by stage at diagnosis. In all stages, the cumulative incidence was highest for patients aged 85 years, with 4.1% (95% CI, 3.7%-4.6%) for stage I disease, 13.9% (95% CI, 13.1%-14.7%) for stage II disease, 39.1% (95% CI, 37.4%-40.9%) for stage III disease, and 78.1% (95% CI, 75.7%-80.5%) for stage IV disease. Cumulative incidences were lower for patients aged 75 to 84 years and younger age groups.
In the multivariable Fine and Gray model including all patients (Table 2) , the adjusted hazard ratios for breast cancer-specific death by age were as follows (all vs ages 55-64 years): aged 35 years, 1.06 (95% CI, 1.01-1.11); aged 36 to 44 years, 0.94 (95% CI, 0.91-0.97); aged 45 to 54 years, 0.91 (95% CI, 0.88-0.93); aged 65 to 74 years, 1.08 (95% CI, 1.05-1.11); aged 75 to 84 years, 1.37 (95% CI, 1.33-1.42); and aged 85 years, 1.65 (95% CI, 1.58-1.73). The relationship between the effects of age and stage of disease was explored as an interaction term in the multivariable Fine and Gray model and reached statistical significance (Wald P<.001). The modification by disease stage is shown in Figure 2 , with a linear relationship of age observed in patients with stage IV disease versus a parabolic relationship in patients with stage I disease, with worse breast cancer-specific outcomes noted among the oldest and youngest age groups.
The adjusted hazard ratios for breast cancer death by age for each of the 16 additional cohorts are shown in Table 2 the reference group was patients aged 55-64 years for all analyses except the HER2-positive and triplenegative cohorts, for which the reference group was patients aged 51-60 years. Among those with HR-positive and HR-negative disease, ages 75 to 84 years and age 85 years were consistently associated with a higher hazard of breast cancer death regardless of stage of disease, and was most notable for the earlier stage cohorts (eg, adjusted hazard ratio for age 85 years, 3.59 [95% CI, 3.12-4.13] for stage I, HR-positive disease; and 2.29 [95% CI, 2.09-2.52] for stage II, HR-positive disease). Among those with HR-negative disease, the adjusted hazard ratios for breast cancer deaths for women aged 85 years ranged from 1.37 to 1.94 (all with P values <.05), with analogous findings for those aged 75 to 84 years. Similar findings by age also were observed for those diagnosed between 2010 and 2012, for whom an age >70 years was associated with a higher hazard of breast cancer death for patients with HER2-positive and triple-negative disease, with the exception of the cohort with stage IV triple-negative disease.
DISCUSSION
In this analysis of nearly 500,000 women with invasive breast cancer living in SEER areas during 2000 through 2012, we observed worse breast cancer-specific survival for women in the oldest age groups for every disease stage and subtype analyzed except stage IV triple-negative disease (for which sample sizes were small), including those with early-stage; advanced stage; and even lowerrisk, HR-positive disease. The current study results were significant even after adjustment for other relevant factors such as race/ethnicity, marital status, and disease characteristics. These findings also are consistent with other studies that have documented worse outcomes in older patients across all stages of disease, in the setting of early-stage disease, and among selected women with HRpositive disease. 2, [4] [5] [6] 10 Although the overall percentage of women with early-stage disease dying of breast cancer was low (1.9% of patients with stage I disease), we observed that this risk more than doubled for older patients. Furthermore, approximately 39.1% of the oldest patients with stage III disease died as a result of breast cancer compared with 26.6% overall. The current study results are sobering given the increasing numbers of older patients anticipated to develop breast cancer within our aging US population in the coming years. 13 The reasons for the worse outcomes noted among older patients remain unclear but are likely multifactorial. One important factor is differences in the receipt of treatment such as undertreatment or lower treatment intensity. It is well established that receipt of adjuvant chemotherapy, trastuzumab, and hormonal therapy reduces the risk of disease recurrence and death across all age groups, [14] [15] [16] [17] yet multiple studies have documented suboptimal systemic treatment and adherence for older patients, including the omission of efficacious treatments, the receipt of lower intensity and/or nonguideline treatment, or poor adherence to hormonal therapy. 2, [18] [19] [20] [21] [22] [23] [24] Although evidence supports the safe omission of local therapies such as radiotherapy, 25,26 breast surgery, 27 and lymph node surgery [28] [29] [30] without a compromise in survival in the setting of lower risk, HR-positive disease, to the best of our knowledge no study to date has demonstrated the safety of the routine omission of systemic therapies for older patients (and in particular hormonal therapy) except in patients with the lowest-risk cancers. 31 It is possible that the larger observed age-related differences in outcomes noted among those with earlier stage cancers in the current study occurred because the underuse of adjuvant systemic treatment has a disproportionate impact on these patients compared with those with metastatic disease, although this hypothesis could not be confirmed in the current study.
Undoubtedly, undertreatment of breast cancer in older patients may be appropriate in some cases in which competing risks and toxicity concerns take priority, but there are likely many situations in which older patients will benefit from a more optimized treatment approach. Important work currently is underway to better establish one's functional age and predict risk of toxicity, all of which will better inform treatment decisions in the near future. [32] [33] [34] Patient preferences also may contribute to undertreatment, which would be appropriate if the care reflects the values and preferences of informed patients. Nevertheless, the lack of prospective clinical trial data, guidelines, or even expert consensus regarding treatments for older patients and patients with comorbidity creates substantial challenges to informed decision making among older patients. Evidence suggests that such uncertainty is associated with substantial variability in physicians' treatment recommendations. 35 In addition to treatment disparities, variable disease biology also may contribute to the worse outcomes observed for older patients. Although "higher risk" breast cancer subtypes such as triple-negative and HER2-positive cancers occur less frequently in older patients compared with younger patients, 1 differences in biology and the genetic underpinnings of breast cancer likely are still present, even among women with similar disease subtypes and in those with HR-positive, "lower risk" cancers. 10, 36, 37 Unfortunately, older patients are largely underrepresented in tissue-based genomic studies, 38 resulting in a lack of detailed understanding of the genetic differences in cancers by age and their impact on outcomes.
It is important to acknowledge that the findings of the current study also may be partially explained by the presence of lead-time bias, because women aged 50 to 70 years have higher screening mammography rates compared with older women, 39 thereby leading to more lower risk cancers diagnosed among these women, with a longer lead time from diagnosis to death. However, US mammography use data from 2010 have demonstrated small differences in mammography use over the prior 2 years for women aged 50 to 74 years compared with those aged >75 years (79.7% vs 73.0%), making it unlikely that differences in screening rates fully explain the current study findings. Furthermore, our observations regarding worse breast cancer-specific survival were consistent across disease stages and subtypes, even among patients with earlier stage triple-negative cancers, which are less likely to be detected mammographically. 40 In the current large, population-based study, we examined outcomes by age in multiple subcohorts, providing new and updated epidemiologic data regarding how age may impact breast cancer-specific survival across disease stages and subtypes. However, we acknowledge several important limitations. First, we lacked extended follow-up for some patients, and analyses of those with HER2positive and triple-negative disease were limited to individuals diagnosed between 2010 and 2012. Second, we had no information regarding comorbidity, performance status, use of mammography or whether cancers were detected by mammography, and receipt of systemic therapy, nor did we have information concerning treatment decision making. Thus, the degree to which undertreatment versus adherence contributed to the findings herein could not be determined. Third, given the lack of data regarding disease recurrence within the SEER registry, the outcomes for patients with metastatic breast cancer could only be examined among those with de novo stage IV disease. Fourth, detailed information regarding important factors such as individualized socioeconomic variables is not available in SEER but has been shown to impact outcomes. Finally, we focused on cause of death to understand breast cancerspecific outcomes; however, cause-of-death data are subject to misclassification. Reassuringly, the results of the current study demonstrated higher rates of non-breast cancer deaths for older patients at each stage, but with an increase in the risk of breast cancer death with increasing stage of disease, which is consistent with what would be expected.
With an increasing number of older patients expected to develop breast cancer in the coming decades, understanding and addressing disparities for older patients is an urgent clinical and research priority. Future studies in older patients should assess reasons for undertreatment in these individuals because the challenges in treating this population are distinct from those noted in other subgroups. This will require novel approaches that facilitate the more active engagement of frail and nonfrail older patients in clinical research.
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